Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of thoracic radiotherapy plus anlotinib in unresectable stage III NSCLC intolerant to concurrent chemoradiation
ChiCTR2200060712Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Safety within 3 months from start of radiotherapy, Objective remission rate within 3 months and 1 more. Started Jun 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200060712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060712.